Evaluation of a novel Vi conjugate vaccine in a murine model of salmonellosis

Vaccine. 2006 May 15;24(20):4312-20. doi: 10.1016/j.vaccine.2006.03.002. Epub 2006 Mar 20.


Immunisation of BALB/c mice with a vaccine containing Vi polysaccharide conjugated to the Klebsiella pneumoniae outer membrane 40 kDa protein (rP40), in combination with Escherichia coli heat-labile toxin adjuvant (LT), elicited anti-Vi IgG antibodies after administration using different routes. Testing of the immune serum in opsonisation assays demonstrated the specific enhancement of Vi-positive bacterial uptake by cultured murine bone marrow derived macrophages. Intra-peritoneal challenge of mice immunised with the Vi-based vaccine elicited a degree of protection against virulent Vi+ Salmonella enterica serovar typhimurium (S. typhimurium). In contrast, Vi vaccination did not confer protection against oral challenge with virulent Vi-positive S. typhimurium or S. dublin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bacterial Vaccines / immunology*
  • Disease Models, Animal*
  • Drug Evaluation, Preclinical
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Mice
  • Mice, Inbred BALB C
  • Polysaccharides, Bacterial / immunology*
  • Salmonella Infections / immunology
  • Salmonella Infections / prevention & control*


  • Bacterial Vaccines
  • Polysaccharides, Bacterial
  • capsular polysaccharide, Salmonella